Completed PHASE1 INTERVENTIONAL 2-arm NCT01923207

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects

Sponsor: Dyax Corp.

Conditions Hereditary Angioedema (HAE)

Interventions DX-2930 Placebo

Updated 8 times since 2017 Last updated: May 13, 2021 Started: Aug 12, 2013 Primary completion: Jan 7, 2014 Completion: Jan 7, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hereditary Angioedema (HAE) and is currently completed. Dyax Corp. leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2021 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dyax Corp.
Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States